News

THOUSAND OAKS, Calif. and DUBLIN, Sept. 1, 2023 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Horizon Therapeutics plc (NASDAQ:HZNP) today announced the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen’s acquisition of Horizon.

As a result of the consent order agreement, Amgen and Horizon expect that the parties will jointly file stipulated proposed orders to dismiss the preliminary injunction motion and dissolve the temporary restraining order (TRO) in the U.S. District Court for the Northern District of Illinois, and that Amgen and Horizon will quickly seek the final approvals required under Irish law to close the acquisition.

Rockville, Maryland – September 13, 2023 – BioHealth Innovation, Inc. (BHI), a leading regional innovation intermediary, is thrilled to announce the five outstanding finalists for the 8th Annual BioHealth Capital Region Crab Trap competition. The Crab Trap is a competition designed to identify and showcase promising life sciences and biotechnology startups from around the world. These finalists have demonstrated exceptional innovation, vision, and potential to significantly impact the healthcare industry.

ARLINGTON, Va.–(BUSINESS WIRE)–The Accelerate Investor Conference is back for its third year at George Mason University’s Arlington Campus, November 1-2, 2023. Spurring the region’s innovation and entrepreneurship engagement to a new level, the conference will showcase the Virginia, Maryland, and metropolitan DC region as a destination for business development, venture investment, and job creation.

BETHESDA, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company has received approval from the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1 clinical study of its lead drug candidate GT-02287 in development for GBA1-Parkinson’s disease (GBA1-PD). Dosing in healthy volunteers to assess the safety and pharmacokinetics of GT-02287 is expected to begin in the near term.

GAITHERSBURG, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the completion of dosing (last subject last dose) in its 48-week Phase 2 MOMENTUM trial evaluating the efficacy and safety of pemvidutide in subjects with obesity or overweight. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis (NASH).

BELTSVILLE, Md., Sept. 07, 2023 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a review article in the online journal Frontiers in Immunology, highlighting the need for targeting tumor collagen in the extracellular matrix (ECM) in the tumor microenvironment to enhance anti-tumor immunity.

“Emerging data on the effects of dysregulated collagen in the ECM show that it modulates accessibility and activity of immune cells within the TME, leading to suboptimal oncology treatment outcomes,” said Solomon Langermann, Ph.D., NextCure’s chief scientific officer. “A key aspect of what we highlighted in this review is that an expanded understanding and cross-fertilization within the fields of tumor matrix biology, cancer biology, and immunology will contribute to improving the efficacy of cancer therapeutics. Importantly, it will enable the development of new classes of therapeutics to address the unmet needs of cancer patients who do not benefit from current therapies. This is a key focus of our ongoing NC410 clinical trial.”

ROCKVILLE, Md., Sept. 09, 2023 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announces the presentation of two posters at Psych Congress 2023 with new data showing improved efficacy in children ages 6 years and older with ADHD when Qelbree is added to a stimulant, as well as in adults with ADHD who undergo long-term treatment with Qelbree.

“While ADHD is recognized as one of the most common psychiatric diagnoses, affecting approximately 16.1 million individuals in the United States, patients are in need of alternative or additional options to stimulants that allow them to manage their symptoms with a safe and tolerable treatment option,” says Jonathan Rubin, Chief Medical Officer and Senior Vice President of Research & Development. “The new Qelbree data presented during Psych Congress 2023 reinforce the efficacy and safety of our novel nonstimulant treatment in addition to existing stimulant therapy in children ages 6 and older with ADHD and in a long-term setting in adults with ADHD.”

One week away from the 9th Annual BioHealth Capital Region Forum (https://bit.ly/BHCRForum2023), a cornerstone event for anyone involved in the biopharma sector. Scheduled for September 19th and 20th at the US Pharmacopeia in Rockville, Maryland, this year’s forum promises to be an enriching experience for all attendees. Even better, thanks to the generosity of our sponsors, attendance is entirely free of cost!

A Gathering of Minds

The forum is a unique confluence of thought leaders, industry executives, academic pioneers, and government officials. This year, the keynote addresses promise to be particularly illuminating. Rachel King, the CEO of BIO, will speak on biotechnology’s accomplishments and challenges in her talk titled “Biotechnology: What We’ve Accomplished and the Challenges Before Us.” On the other end of the spectrum, Lance Liotta, Co-Director of the Center for Applied Proteomics and Molecular Medicine at George Mason University, will explore the cutting-edge intersection of AI and BioHealth in his keynote, “Hijacking Cellular Communications using AI Tools: A New Frontier in BioHealth.”

Your Invitation to apply to a Key Investment Event in Rockville, Maryland Awaits

There’s still time if you haven’t yet marked your calendar for the 6th Annual BioHealth Capital Region Investment Conference. The one-day event will also be held at the US Pharmacopeia (USP) in Rockville, Maryland, and is free to attend, thanks to our generous sponsors. Applications to attend are due by September 12^th!

A Unique Investment Opportunity: September 21st

The Investment Conference brings together investors and companies seeking funding. With a strong track record of fostering successful financial engagements, this conference is an unparalleled opportunity for those eyeing transformative funding.